Quick Answer
GeneDx Holdings Corp. reported Total Revenue of $427.54 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +40.0% in Total Revenue from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $46.66 million | Q2 2020: $30.10 million | Q3 2020: $38.61 million | Q4 2020: $63.96 million | Q1 2021: $64.20 million | Q2 2021: $47.02 million | Q3 2021: $43.18 million | Q4 2021: $57.80 million | Q1 2022: $53.94 million | Q2 2022: $36.17 million | Q3 2022: $83.23 million | Q1 2023: $43.14 million | Q2 2023: $48.71 million | Q3 2023: $53.30 million | Q1 2024: $62.42 million | Q2 2024: $70.51 million | Q3 2024: $76.87 million | Q1 2025: $87.12 million | Q2 2025: $102.69 million | Q3 2025: $116.74 million.
- Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Total Revenue has grown by 117.9%.
- Historical annual values: Fiscal year 2025: $427.54 million | Fiscal year 2024: $305.45 million | Fiscal year 2023: $202.57 million | Fiscal year 2022: $234.69 million | Fiscal year 2021: $212.20 million | Fiscal year 2020: $179.32 million | Fiscal year 2019: $196.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: